OCUL Form 4: Pravin Dugel Transfers 49,754 Shares to Spouse

Pravin Dugel, Executive Chairman, President and CEO of Ocular Therapeutix, Inc. (OCUL), reported intra-family transfers on Form 4.

Rhea-AI Filing Summary

Pravin Dugel, Executive Chairman, President and CEO of Ocular Therapeutix, Inc. (OCUL), reported intra-family transfers on Form 4. On 09/09/2025 he transferred 49,754 shares of the company's common stock to his spouse for no consideration and, on the same date, a corresponding entry shows 49,754 shares recorded as acquired indirectly by spouse. After the reported transactions, Mr. Dugel directly owned 3,177,490 shares and had indirect ownership stakes of 250,361 shares through the Pravin Dugel 2024 Irrevocable Trust and 49,754 shares held by his spouse. The Form 4 was signed by an attorney-in-fact on 09/11/2025.

Insights

Financial Analyst

TL;DR: Insider reported a no-consideration transfer of 49,754 shares to spouse; overall insider ownership remains substantial and unchanged in economic exposure.

The filing documents a routine intra-family transfer rather than a market sale, indicating no proceeds were realized and no immediate dilution or liquidity event occurred. Direct ownership of 3,177,490 shares remains dominant for the reporting person while additional indirect holdings total 300,115 shares combined (spouse and trust). For investors, this is a disclosure of ownership movement without an indicated change in investment intent or company fundamentals.

Corporate Governance Expert

TL;DR: The Form 4 records a permitted transfer to a spouse and notes officer/director status; disclosure meets Section 16 reporting norms.

This transaction appears documented to satisfy Section 16 transparency requirements. The reporting person is identified as both an officer and director, and the filing includes the required signature via attorney-in-fact. No derivative transactions or compensatory grants are reported. From a governance perspective, the report is procedural and does not indicate an immediate governance or control change.

Insider Trade Summary

99,508 shares gifted

Gift 3 txns

Insider Dugel Pravin

Role See Remarks

Type	Security	Shares	Price	Value
Gift	Common Stock	49,754	$0.00	$0.00
Gift	Common Stock	49,754	$0.00	$0.00
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 3,177,490 shares (Direct); Common Stock — 49,754 shares (Indirect, By spouse); Common Stock — 250,361 shares (Indirect, By Pravin Dugel 2024 Irrevocable Trust)

Footnotes (1)

1. F1. On September 9, 2025, the reporting person transferred 49,754 shares to his spouse for no consideration.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What transaction did Pravin Dugel report on Form 4 for OCUL?

The Form 4 reports that on 09/09/2025 Mr. Dugel transferred 49,754 shares of OCUL common stock to his spouse for $0 consideration.

How many OCUL shares does Pravin Dugel directly own after the reported transaction?

After the reported transactions, Mr. Dugel directly owns 3,177,490 shares of OCUL common stock.

Are there any indirect holdings disclosed for Mr. Dugel in the filing?

Yes. The filing discloses 49,754 shares indirectly held by his spouse and 250,361 shares indirectly held by the Pravin Dugel 2024 Irrevocable Trust.

Did the Form 4 show any sales or cash proceeds from the transaction?

No. The transfer to the spouse was reported for $0, indicating no sale proceeds were received.

Who signed the Form 4 and when was it signed?

The Form 4 was signed by Todd Anderman, Attorney-in-Fact for Pravin Dugel on 09/11/2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/11/2025 - 04:06 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dugel Pravin

(Last) (First) (Middle)

C/O OCULAR THERAPEUTIX, INC.

15 CROSBY DRIVE

(Street)

BEDFORD MA 01730

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
OCULAR THERAPEUTIX, INC [ OCUL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
09/09/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/09/2025		G(1)		49,754	D	$0	3,177,490	D
Common Stock	09/09/2025		G(1)		49,754	A	$0	49,754	I	By spouse
Common Stock								250,361	I	By Pravin Dugel 2024 Irrevocable Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On September 9, 2025, the reporting person transferred 49,754 shares to his spouse for no consideration.

Remarks:

Executive Chairman, President and CEO

	/s/ Todd Anderman, Attorney-in-Fact for Pravin Dugel	09/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.